Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs.
Knowledge of the health care costs associated with neuropathic pain is limited. Existing studies have not directly compared the health care costs of different neuropathic pain conditions, and patients with neuropathic pain have not been compared with control subjects with the same underlying conditions (for example, diabetes). To determine health care costs associated with postherpetic neuralgia (PHN) and painful diabetic peripheral neuropathy (DPN), patients with these conditions were selected from 2 different administrative databases of health care claims and respectively matched to control subjects who had a diagnosis of herpes zoster without persisting pain or a diagnosis of diabetes without neurological complications using propensity scores for demographic and clinical factors. Total excess health care costs attributable to PHN and painful DPN and excess costs for inpatient care, outpatient/professional services, and pharmacy expenses were calculated. The results indicated that the annual excess health care costs associated with peripheral neuropathic pain in patients of all ages range from approximately $1600 to $7000, depending on the specific pain condition. Total excess health care costs associated with painful DPN were substantially greater than those associated with PHN, which might reflect the great medical comorbidity associated with DPN.


CONCLUSIONS
The data demonstrate that the health care costs associated with 1 peripheral neuropathic pain condition cannot be extrapolated to other neuropathic pain conditions. The results also increase understanding of the economic burden of PHN and painful DPN and provide a basis for evaluating the impact on health care costs of new interventions for their treatment and prevention.
Dworkin
Robert H
RH
Departments of Anesthesiology and Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA. robert_dworkin@urmc.rochester.edu
Malone
Daniel C
DC
Panarites
Christopher J
CJ
Armstrong
Edward P
EP
Pham
Sissi V
SV
D000368:Aged; D000700:Analgesics / Q000191:economics / Q000627:therapeutic use; D015331:Cohort Studies; D015897:Comorbidity; D019992:Databases as Topic; D003920:Diabetes Mellitus / Q000191:economics / Q000453:epidemiology / Q000628:therapy; D003929:Diabetic Neuropathies / Q000191:economics* / Q000453:epidemiology / Q000628:therapy*; D016527:Drug Costs; D005260:Female; D017048:Health Care Costs / Q000706:statistics & numerical data* / Q000639:trends; D006562:Herpes Zoster / Q000191:economics / Q000453:epidemiology / Q000628:therapy; D006760:Hospitalization / Q000191:economics / Q000706:statistics & numerical data; D006801:Humans; D007297:Inpatients / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D051474:Neuralgia, Postherpetic / Q000191:economics* / Q000453:epidemiology / Q000628:therapy*; D012189:Retrospective Studies
D000700:Analgesics